Intuitive Surgical (ISRG) Q3 2025 Earnings SMASH Expectations! Da Vinci 5 Drives 23% Revenue Surge скачать в хорошем качестве

Intuitive Surgical (ISRG) Q3 2025 Earnings SMASH Expectations! Da Vinci 5 Drives 23% Revenue Surge

🚀 Intuitive Surgical (ISRG) Q3 2025 Earnings SMASH Expectations! Da Vinci 5 Adoption Drives 23% Revenue Surge Intuitive Surgical (ISRG), the global technology leader and pioneer of robotic-assisted surgery, delivered a massive beat for its third-quarter 2025 financial results, announced on October 21, 2025. This video summarizes the key metrics driving the company's strong performance and updated 2025 outlook, which led to the *ISRG stock surging more than 22%* in after-hours trading. Q3 2025 Financial Highlights (ISRG Earnings Beat) Intuitive's total revenue for Q3 2025 reached **$2.51 billion**, marking a 23% increase compared with $2.04 billion in the third quarter of 2024. This revenue figure topped the consensus estimate of $2.41 billion. The robust growth was reflected in profitability: *Non-GAAP Net Income Per Diluted Share (EPS):* $2.40. This beat the analyst forecast of $1.99 by $0.41. *Non-GAAP Net Income:* $867 million, up from $669 million in Q3 2024. *GAAP Net Income Per Diluted Share:* $1.95. *Instruments and Accessories Revenue:* Increased 20% to **$1.52 billion**. Procedure Volume and System Adoption Growth The primary catalyst for the revenue increase was the continued adoption of the da Vinci and Ion platforms. Worldwide procedures (combined da Vinci and Ion) grew approximately *20%* compared with Q3 2024. #### Da Vinci Systems: *Procedure Growth:* Da Vinci procedures grew approximately **19%**. *New System Placements:* The Company placed 427 da Vinci systems (up from 379 in Q3 2024). *Da Vinci 5 Adoption:* Placements included **240 da Vinci 5 systems**, a significant increase from 110 in the year-ago period. *Installed Base:* The da Vinci installed base reached *10,763 systems* as of September 30, 2025, an increase of 13% year-over-year. #### Ion Endoluminal System: *Procedure Growth:* Ion procedures, which perform lung biopsies, surged approximately *52%* compared with Q3 2024. *Installed Base:* The Ion system base grew 30% to **954 systems**. Updated 2025 Financial Outlook Following the strong quarter, Intuitive raised its full-year guidance for 2025: *Worldwide Da Vinci Procedure Growth:* Expected to be approximately *17% to 17.5%* for the full year 2025. (Analysts had called for a lower 16.4% growth). *Non-GAAP Operating Expense Growth:* Expected to be 11% to 13%. CEO Dave Rosa noted the company remains focused on helping customers achieve the **Quintuple Aim**: delivering better patient care, improving patient and care team experiences, expanding access to high-quality care, and reducing overall care costs. *** #### 📊 Key Q3 2025 Data Points: *Total Revenue:* $2.51 Billion *Non-GAAP EPS:* $2.40 *Total Procedure Growth:* ~20% *Da Vinci 5 Placements:* 240 *2025 Procedure Guidance:* 17% - 17.5% *Cash Position:* $8.43 Billion *** *Source Information:* This description is based on the Intuitive press release dated October 21, 2025, discussing financial results for the quarter ended September 30, 2025. The information contained herein relies on the provided excerpts and may include non-GAAP financial measures, which are used by management for evaluating performance. *For more detailed financial data and historical reconciliations, refer to the Investor Relations section of the Intuitive website.* \#IntuitiveSurgical #ISRG #Q3Earnings #RoboticSurgery #DaVinci5 #StockMarketNews #HealthcareTech #ISRGStock #EarningsReport